Empire Genomics Names Dr. John J. Rushton as Chief Operating Officer

2015-10-06 13:58:10

Date: October 6, 2015

Buffalo, NY – Empire Genomics announces today it has appointed Dr. John J. Rushton as Chief Operating Officer. As COO, Dr. Rushton will be responsible for overseeing day-to-day operations and ensuring company alignment with corporate strategies to enhance service delivery to Empire Genomics’ customers worldwide. He brings a wealth of experience having worked at both large and rapidly growing molecular diagnostic firms. He will provide operational, scientific, technical, and leadership support as Empire Genomics expands its footprint and testing options.

"I am very excited to join the Empire Genomics team with their focus on growth in the area of cancer diagnostics and expanding the precision medicine options to meet the patient’s needs," stated Dr. John Rushton.

Prior to relocating to Buffalo, Dr. Rushton was the Science, Technology and Innovation Director at Pathology Associates Medical Laboratories (PAML) in Spokane, WA. PAML is the 4th largest clinical diagnostic laboratory in the United States. He also worked at Signature Genomics Laboratory (SGL) in Spokane, WA with a focus on test expansion and business development. SGL was a state-of-the-art array-based comparative genomic hybridization (array CGH) diagnostic laboratory. He sits as an expert reviewer for the Life Sciences Discovery Fund of Washington State that supports the commercialization of translational research to improve Washington resident healthcare through scientific business development. Dr. Rushton offers a wide breadth of industry experience which includes commercialization, regulatory compliance and project management.

Dr. Rushton earned a doctorate in Biomedical Sciences, with a focus on genetics, from the University of Pittsburgh (PITT) School of Medicine in 1992. He also received an MBA from the University of New Mexico (UNM) Anderson School of Management in 2005. He held postdoctoral fellowships at PITT School of Medicine and UNM School of Medicine, focusing on molecular biology approaches to the study of cancer and infectious diseases at both. Following his fellowships, Dr. Rushton joined the faculty at UNM School of Medicine with a focus on biomarkers of cancer and infectious disease susceptibility. He was promoted to Director of the UNM School of Medicine Center of Infectious Disease and Immunology Sequencing, Microarray and Biological Safety Level 3 core laboratories, and was involved in strategic technology investments while at UNM.

"Hiring an executive of Dr. Rushton’s caliber is a tremendous win for our company. I look forward to working side by side with him as we continue to accelerate the growth of our business and continue to offer best in class personalized healthcare services to our clients," commented Anthony Johnson, President and Chief Executive Officer.